SCHEMBL10090300

SCHEMBL10090300

O=C1NC(=S)S/C1=C\c1cc(Br)ccc1OCCCc1ccnc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTP4A3 O75365 10/20 0.62
▸ GSK3B P49841 2/20 0.49
▸ PTPN1 P18031 3/20 0.48
▸ MGAM O43451 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ SI P14410 1/20 0.44
▸ MGAM2 Q2M2H8 1/20 0.44
▸ PIM1 P11309 2/20 0.44
▸ PIK3CD O00329 1/20 0.44
▸ CSNK2A2 P19784 1/20 0.44
▸ PIK3CA P42336 1/20 0.44
▸ PIK3CG P48736 1/20 0.44
▸ CLK1 P49759 1/20 0.44
▸ CLK3 P49761 1/20 0.44
▸ CSNK2B P67870 1/20 0.44
▸ CSNK2A1 P68400 1/20 0.44
▸ DYRK1A Q13627 1/20 0.44
▸ HASPIN Q8TF76 1/20 0.44
▸ DYRK2 Q92630 1/20 0.44
▸ MYLK2 Q9H1R3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2065588 0.90 PTP4A3 (0.64) PTP4A3GSK3BPTPN1MGAMGAA
SCHEMBL2066571 0.83 PTP4A3 (0.80) PTP4A3GSK3BPTPN1
SCHEMBL10090209 0.83 PTP4A3 (0.80) PTP4A3GSK3BPTPN1
SCHEMBL2066568 0.83 PTP4A3 (0.80) PTP4A3GSK3BPTPN1
SCHEMBL10090301 0.81 PTP4A3 (0.62) PTP4A3GSK3BPTPN1MGAMGAA
SCHEMBL2066221 0.81 PTP4A3 (0.62) PTP4A3GSK3BPTPN1MGAMGAA
SCHEMBL10090242 0.80 PTP4A3 (0.67) PTP4A3GSK3BPTPN1MGAMGAA
SCHEMBL2065526 0.80 PTP4A3 (0.67) PTP4A3GSK3BPTPN1MGAMGAA
SCHEMBL2065524 0.80 PTP4A3 (0.67) PTP4A3GSK3BPTPN1MGAMGAA
SCHEMBL2065602 0.80 PTP4A3 (0.82) PTP4A3GSK3BPTPN1CISD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same PTPRR, PTPRG, PTPRS PTP4A3 28/4885GSK3B 390/4885PTPN1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback